Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17943275 | 0.95 | LGALS9 (0.44) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL17943280 | 0.90 | ADORA2A (0.44) | ADORA1ADORA2AADORA3HPGDSMN1; SMN2 | |
| SCHEMBL27093274 | 0.89 | ADORA2A (0.41) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL20219708 | 0.89 | HPGD (0.38) | ADORA1HPGDSMN1; SMN2 | |
| SCHEMBL20219940 | 0.87 | SMN1; SMN2 (0.37) | ADORA1HPGDSMN1; SMN2 | |
| SCHEMBL17943264 | 0.86 | ADORA2A (0.43) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL17943276 | 0.84 | ADORA2A (0.43) | ADORA2AADORA2B | |
| SCHEMBL27093440 | 0.84 | LGALS9 (0.42) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL17943262 | 0.82 | SLC28A2 (0.44) | ADORA1ADORA2AADORA3ADORA2BHPGD | |
| SCHEMBL28076665 | 0.82 | DNMT1 (0.52) | ADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | disclosed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160348112-A1 | Compositions and Methods for Detecting Microorganisms | SOMALOGIC OPERATING CO. INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | ADORA1 66/4885ADORA2A 61/4885ADORA3 54/4885 |
| US-20160215013-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | ADORA1 66/4885ADORA2A 61/4885ADORA3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.